News › Clinical Practice, Industry News, Patient Care

FDA Clears CoolSculpting for Treatment of ‘Double Chin’

February 26, 2018

The U.S. Food and Drug Administ­ration has cleared CoolSculpting as the first and only non-surgical fat reduction technology for use to improve the appearance of lax tissue and submental fat treatments, or “double chin,” according to Allergan.
“Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking non-invasive aesthetic treatments,” said David Nicholson, chief research and development officer at Allergan. “A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73% of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.”
Read more at Skin Inc >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement